Physician profile
Ana E Corteguera
NPI 1699700765
$9,095.10
in general payments reported to CMS, 2019-2025
40 companies · $2,414 in 2025
The $2,414 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $322 · 2020: $384 · 2021: $785 · 2022: $1,072 · 2023: $2,080 · 2024: $2,039 · 2025: $2,414.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,515 · Education: $16.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,515.18 |
| Education | $16.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,054.33 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $930.46 | 2019-2025 | Ubrelvy, Linzess, Qulipta |
| Abbott Laboratories | $812.84 | 2023-2025 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $668.71 | 2020-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Lilly USA, LLC | $567.28 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $538.32 | 2022-2025 | |
| Sanofi-Aventis U.S. LLC | $427.74 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $419.75 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Takeda Pharmaceuticals U.S.A., INC. | $245.69 | 2021-2025 | Trintellix |
| Merck Sharp & Dohme LLC | $243.09 | 2019-2025 | Gardasil 9, Capvaxive, Verquvo |
| Ibsa Pharma INC. | $237.06 | 2019-2025 | Licart, Tirosint, Flector |
| Eisai INC. | $205.07 | 2019-2022 | |
| Astellas Pharma US INC | $201.13 | 2019-2024 | Veozah, Myrbetriq |
| Amgen INC. | $200.91 | 2019-2025 | Repatha, Otezla, Otezla |
| Shield Therapeutics INC | $192.14 | 2023-2025 | Accrufer |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $175.15 | 2023-2025 | Cologuard Collection Kit |
| Dexcom, INC. | $138.51 | 2024-2025 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $113.72 | 2019-2025 | Jardiance |
| Currax Pharmaceuticals LLC | $96.46 | 2022-2025 | Contrave, Onzetra Xsail |
| Allergan, INC. | $80.15 | 2020 | |
| Medtronic, INC. | $61.53 | 2023 | Harmony |
| Renalytix Ai, INC. | $46.43 | 2025 | Kidneyintelx Blood Collection Convenience Kit |
| Janssen Pharmaceuticals, INC | $44.01 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $43.50 | 2019-2023 | Xifaxan, Trulance |
| Hologic Sales and Service, LLC | $41.32 | 2022-2025 | Thinprep 2000 Processor, Aptima |
| Inspire Medical Systems, INC. | $39.86 | 2024 | Inspire |
| Sumitomo Pharma America, INC. | $31.29 | 2025 | Gemtesa |
| Bayer Healthcare Pharmaceuticals INC. | $26.94 | 2022 | |
| Organon LLC | $25.44 | 2023 | Nexplanon |
| Ironshore Pharmaceuticals INC. | $20.27 | 2019 | |
| Amarin Pharma, INC. | $20.22 | 2021 | |
| Alvogen INC | $20.05 | 2024 | Teriparatide |
| Azurity Pharmaceuticals, INC. | $19.12 | 2024 | Horizant |
| Dynavax Technologies Corporation | $17.91 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $17.68 | 2024 | Rexulti |
| Optinose US, INC. | $17.20 | 2024 | |
| Kowa Pharmaceuticals America, INC. | $15.59 | 2021 | |
| Redhill Biopharma INC. | $14.64 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $11.85 | 2019 | |
| Corium, LLC | $11.74 | 2023 | Azstarys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ana Corteguera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.